My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody

Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C071P Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody 1 mg 175.00
C071P Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody 5 mg 600.00
C071P Sacituzumab Biosimilar, Trop-2 Monoclonal Antibody 20 mg 1600.00
C071P.05 Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg 5 mg 900.00
C071P.05 Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg 20 mg 2400.00

C071P: Sacituzumab Biosimilar, Human Trop-2 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The monoclonal antibody sacituzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The monoclonal antibody sacituzumab biosimilar specifically binds to the human Trop-2 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by sacituzumab.
Form of Antibody: 0.2 uM filtered solution, pH 6.2, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The monoclonal antibody sacituzumab is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.


What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.

Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy